無料プレビュー

Pacira BioSciences, Inc. (PCRX) · NASDAQ Global Select

プロフィール

Pacira BioSciences, Inc. is a biopharmaceutical company delivering non-opioid pain therapies. Its commercialized products include EXPAREL (bupivacaine liposome injection for postsurgical pain), ZILRETTA (triamcinolone acetonide extended-release injection for osteoarthritis knee pain), and iovera° (handheld cryoanalgesia device for pain management). The company operates three primary product lines plus a pipeline including PCRX-201, a gene therapy in Phase 2 development for knee osteoarthritis. Products are distributed to U.S. healthcare providers including surgeons, anesthesiologists, orthoped

主要指標

株価: $36.35 (-0.11%)
時価総額: 14億ドル
PER（今期予想）: 12.6
PBR: 2.1
配当利回り: —
52週レンジ: $18.80 – $36.46
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ Global Select
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、ITCI Intra-Cellular Therapies, Inc.、CTLT Catalent, Inc.、ELAN Elanco Animal Health Incorporated

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09